Exact Mass: 418.2620144
Exact Mass Matches: 418.2620144
Found 250 metabolites which its exact mass value is equals to given mass value 418.2620144,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Simvastatin
C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor D009676 - Noxae > D000963 - Antimetabolites Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; EAWAG_UCHEM_ID 3144 CONFIDENCE standard compound; INTERNAL_ID 1128
3alpha,12alpha-Dihydroxy-5beta-pregnan-20-one diacetate
Simvastatin
Simvastatin is a hypolipidemic drug belonging to the class of pharmaceuticals called statins. It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus; Simvastatin is a powerful lipid-lowering drug that can decrease low density lipoprotein (LDL) levels by up to 50 percent. It is used in doses of 5 mg up to 80 mg. Higher doses (160 mg) have been found to be too toxic, while giving only minimal benefit in terms of lipid lowering. There is no real effect on HDL and triglyceride levels.; Simvastatin (INN) is a hypolipidemic drug belonging to the class of pharmaceuticals called statins. It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus; The drug is the form of an inactive lactone that is hydrolized after ingestion to produce the active agent. It is a white, nonhygroscopic, crystalline powder that is practically insoluble in water, and freely soluble in chloroform, methanol and ethanol; Ezetimibe/simvastatin is a combination product to lower lipids and marketed as Vytorin. [HMDB] Simvastatin is a hypolipidemic drug belonging to the class of pharmaceuticals called statins. It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus; Simvastatin is a powerful lipid-lowering drug that can decrease low density lipoprotein (LDL) levels by up to 50 percent. It is used in doses of 5 mg up to 80 mg. Higher doses (160 mg) have been found to be too toxic, while giving only minimal benefit in terms of lipid lowering. There is no real effect on HDL and triglyceride levels. Simvastatin (INN) is a hypolipidemic drug belonging to the class of pharmaceuticals called statins. It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus; The drug is the form of an inactive lactone that is hydrolized after ingestion to produce the active agent. It is a white, nonhygroscopic, crystalline powder that is practically insoluble in water, and freely soluble in chloroform, methanol and ethanol; Ezetimibe/simvastatin is a combination product to lower lipids and marketed as Vytorin. C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor D009676 - Noxae > D000963 - Antimetabolites Simvastatin. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=79902-63-9 (retrieved 2024-10-09) (CAS RN: 79902-63-9). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
Cavipetin D
Cavipetin D is found in mushrooms. Cavipetin D is a constituent of the edible mushroom (Boletinus cavipes) Constituent of the edible mushroom (Boletinus cavipes). Cavipetin D is found in mushrooms.
(1R,3S,7R,8R,8As)-8-{2-[(2R,4S)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
Simvastatin is a hypolipidemic drug belonging to the class of pharmaceuticals called statins. It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus; Simvastatin is a powerful lipid-lowering drug that can decrease low density lipoprotein (LDL) levels by up to 50 percent. It is used in doses of 5 mg up to 80 mg. Higher doses (160 mg) have been found to be too toxic, while giving only minimal benefit in terms of lipid lowering. There is no real effect on HDL and triglyceride levels.; Simvastatin (INN) is a hypolipidemic drug belonging to the class of pharmaceuticals called statins. It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus; The drug is the form of an inactive lactone that is hydrolized after ingestion to produce the active agent. It is a white, nonhygroscopic, crystalline powder that is practically insoluble in water, and freely soluble in chloroform, methanol and ethanol; Ezetimibe/simvastatin is a combination product to lower lipids and marketed as Vytorin. [HMDB]
MG(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/0:0/0:0)
MG(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/0:0/0:0)
MG(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/0:0/0:0)
MG(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/0:0/0:0)
MG(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/0:0/0:0)
MG(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/0:0)
MG(0:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/0:0)
MG(0:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/0:0)
MG(0:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/0:0)
MG(0:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/0:0)
MG(0:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
Ophiopogonoside A
Ophiopogonoside A is a natural product found in Ophiopogon japonicus and Liriope muscari with data available.
3alpha-Angeloyloxy-18-hydroxy-ent-labd-8(17)-13E-dien-15-oic acid
6alpha-Angeloyloxy-7-oxo-13,14-dihydrokolavenic acid
Aplysinoplide B
A sesterterpenoid isolated from the marine sponge Aplysinopsis digitata that exhibits cytotoxicity against P388 mouse leukemia cells.
12beta,16alpha,20-Trihydroxy-17-scalaren-19,20-olide
(1R,4R,5R,7R,10S)-10,11,15-trihydroxyguaiane 11-O-beta-D-glucopyranoside
6alpha,15(S),23-trihydroxy-labd-8(22),13(14),17-trien-16(S),19-olide
8alpha,15(S)-dihydroxy-23,6alpha-epoxy-labd-13(14),17-dien-16(S),19-olide
Di-Ac-(3beta,5alpha,6alpha)-3,6-Dihydroxypregnan-20-one
6alpha,8alpha,23-trihydroxy-labd-13(14),15,17-trien-16,19-olide
Di-Ac-(3beta,5alpha,16alpha)-3,16-Dihydroxypregnan-20-one
(2E,4E,6E)-cyclo-[(NMe-L-Ala)-L-Val-(Nalpha-octa-2,4,6-trienoyl-L-Orn)]|sclerotiotide A
C22H34N4O4 (418.25799240000003)
celerioside E|eudesmane-1beta,4alpha,11-triol 11-O-beta-D-glucopyranoside
3alpha-angeloyloxy-2alpha-hydroxy-13,14Z-dehydrocativic acid
6alpha,8alpha-dihydroxy-23-oxo-labd-13(14),17-dien-16(R),19-olide
Di-Ac-(3beta,5beta,17alphaOH)-3,17-Dihydroxypregnan-20-one
9beta-acetoxy-13alpha-hydroxy-3beta-propionoxy-1beta,8beta-trinervita-11,15(17)-diene
2-Acetoxy-5-methoxy-6-methyl-3-[(Z-10-pentadecenyl)-1,4-benzoquinone]
eudesman-3,4alpha,11-triol-11-O-beta-D-glucopyranoside
ent-17-Succinyloxy-15alpha,16alpha-epoxybeyeran-methylester
ent-19-Succinyloxy-15alpha,16alpha-epoxybeyeran-methylester
18-oxo-19-senecioyloxy-ent-clerod-3-en-15-oic acid
3-Ketone,2-(3-methyl-2-butenoyl)----2,3,16,17-Phyllocladanetetrol
2-Methoxy-5-acetoxy-6-methyl-3-[(z)-10-pentadecenyl]-1,4-benzoquinone
(2E,6E)-10-beta-D-glucopyranosyl-1,10,11-trihydroxy-3,7,11-trimethyldodeca-2,6-diene
3-(3-Methylbutanoyl)-(ent-3beta)-3, 9-Dihydroxy-15-kauren-19-oic acid
C22H34N4O4_N-Methyl-N-[(2E,4E,6E)-2,4,6-octatrienoyl]valylalanylprolinamide
C22H34N4O4 (418.25799240000003)
Gly Lys Lys Ser
Gly Lys Ser Lys
Gly Ser Lys Lys
Lys Gly Lys Ser
Lys Gly Ser Lys
Lys Lys Gly Ser
Lys Lys Ser Gly
Lys Ser Gly Lys
Lys Ser Lys Gly
Ser Gly Lys Lys
Ser Lys Gly Lys
Ser Lys Lys Gly
Cavipetin D
2,2-dimethylbutanoic acid [(7S,8S)-8-[2-[(2R)-4-hydroxy-6-oxo-2-oxanyl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] ester
[(1S,3R,7S,8R,8aS)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
[(1R,3R,7S,8R,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
(1-butanoyloxy-3-hydroxypropan-2-yl) (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
(1-acetyloxy-3-hydroxypropan-2-yl) (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
3beta-hydroxy-5beta-pregnan-20-one hemisuccinate
A sterol ester that is the O-succinoyl derivative of 3beta-hydroxy-5beta-pregnan-20-one.
3beta-hydroxy-5alpha-pregnan-20-one hemisuccinate
A sterol ester that is the O-succinoyl derivative of 3beta-hydroxy-5alpha-pregnan-20-one.
2-[(5,8-dihydroxy-2-isopropyl-4a,8-dimethyl-octahydronaphthalen-1-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
(1r,3s,4r,7r,8e,11s,12r)-12-[(2s,3z,5s)-5,6-dihydroxy-6-methylhept-3-en-2-yl]-4-hydroxy-1,4-dimethyl-6-oxotricyclo[9.3.0.0³,⁷]tetradec-8-ene-8-carbaldehyde
(10e,14e)-17-[(2s)-2-hydroxy-5-oxo-2h-furan-3-yl]-6,6,10,14-tetramethylheptadeca-10,14-diene-2,7-dione
n-(2,8-dihydroxy-6-isopropyl-3,4-dimethyl-5-oxo-1,4,7-triazacyclododeca-1,7-dien-9-yl)octa-2,4,6-trienimidic acid
C22H34N4O4 (418.25799240000003)
8-(acetyloxy)-1-ethyl-9a,11a-dimethyl-2-oxo-tetradecahydrocyclopenta[a]phenanthren-7-yl acetate
3-hydroxy-3-isopropyl-6,8a-dimethyl-4-[(2-methylbut-2-enoyl)oxy]-1,2,3a,4,5,8-hexahydroazulen-1-yl 2-methylbut-2-enoate
(5z)-5-[(2s)-2-[(3r,4ar,6s,6as,10as,10br)-6-hydroxy-3,4a,7,7,10a-pentamethyl-octahydro-1h-naphtho[2,1-b]pyran-3-yl]-2-hydroxyethylidene]-4-methylfuran-2-one
3-ethenyl-10-hydroxy-3,4a,7,7,10a-pentamethyl-5-oxo-octahydronaphtho[2,1-b]pyran-8-yl 2-methylbut-2-enoate
2-{[1-hydroxy-1-(hydroxymethyl)-5-isopropyl-7a-methyl-hexahydro-2h-inden-4-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(3ar,7s,16as)-2,7-dihydroxy-10-(hydroxymethyl)-3-[(2s)-1-hydroxypropan-2-yl]-6,14,16a-trimethyl-3ah,4h,7h,8h,9h,12h,13h,16h-cyclopenta[15]annulen-1-one
(2e,4e,6z)-n-[(3s,6s,9s)-2,5-dihydroxy-6-isopropyl-3,7-dimethyl-8-oxo-1,4,7-triazacyclododeca-1,4-dien-9-yl]octa-2,4,6-trienimidic acid
C22H34N4O4 (418.25799240000003)
(2s,3r,4s,5s,6r)-2-{[(3s,6e,10s)-10,11-dihydroxy-3,7,11-trimethyldodeca-1,6-dien-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
4-[(16-hydroxy-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl)oxy]-3-methyl-4-oxobut-2-enoic acid
(4r,5as,5br,7as,11as,11br,13r,13as)-1,4,13-trihydroxy-5b,8,8,11a,13a-pentamethyl-1h,4h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-chryseno[1,2-c]furan-3-one
(5r)-4-[(1r,3e)-1,5-dihydroxy-4-[(3e)-4-methyl-6-(2,6,6-trimethylcyclohex-1-en-1-yl)hex-3-en-1-yl]pent-3-en-1-yl]-5-hydroxy-5h-furan-2-one
(5s)-5-[(1e)-2-[(3r,4ar,6s,6as,10as,10br)-6-hydroxy-3,4a,7,7,10a-pentamethyl-octahydro-1h-naphtho[2,1-b]pyran-3-yl]ethenyl]-5-hydroxy-4-methylfuran-2-one
(5s)-4-[(1r,3e)-1,5-dihydroxy-4-[(3e)-4-methyl-6-(2,6,6-trimethylcyclohex-1-en-1-yl)hex-3-en-1-yl]pent-3-en-1-yl]-5-hydroxy-5h-furan-2-one
(2s,3r,4s,5s,6r)-2-{[(3s,6e,10e)-2,12-dihydroxy-2,6,10-trimethyldodeca-6,10-dien-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(1r,7r,8s,9as,11as)-8-(acetyloxy)-1-ethyl-9a,11a-dimethyl-2-oxo-tetradecahydrocyclopenta[a]phenanthren-7-yl acetate
2-acetoxy-5-methoxy-6-methyl-3-[(z-10'-pentadecenyl)-1,4-benzoquinone]
{"Ingredient_id": "HBIN005110","Ingredient_name": "2-acetoxy-5-methoxy-6-methyl-3-[(z-10'-pentadecenyl)-1,4-benzoquinone]","Alias": "NA","Ingredient_formula": "C25H38O5","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "253","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
2-methoxy-5-acetoxy-6-methyl-3-[(z)-10'-pentadecenyl]-1,4-benzoquinone
{"Ingredient_id": "HBIN005897","Ingredient_name": "2-methoxy-5-acetoxy-6-methyl-3-[(z)-10'-pentadecenyl]-1,4-benzoquinone","Alias": "NA","Ingredient_formula": "C25H38O5","Ingredient_Smile": "CCCCC=CCCCCCCCCCC1=C(C(=O)C(=C(C1=O)OC(=O)C)C)OC","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "13822","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
2-[(2,12-dihydroxy-2,6,10-trimethyldodeca-6,10-dien-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
(1s,4r,7r,9r,10s,13r,14r)-14-hydroxy-14-(hydroxymethyl)-5,5,9-trimethyl-6-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-7-yl 3-methylbut-2-enoate
(2s,3r,4s,5s,6r)-2-{[(3s,6e,10s)-3,10-dihydroxy-2,6,10-trimethyldodeca-6,11-dien-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
2-{2-hydroxy-4,8-dimethyl-10-[(2-methylbut-2-enoyl)oxy]cyclodeca-3,7-dien-1-yl}propyl 2-methylbut-2-enoate
(1r,3as,4r,8s,8as)-1-hydroxy-1-isopropyl-3a,6-dimethyl-8-{[(2z)-2-methylbut-2-enoyl]oxy}-2,3,4,7,8,8a-hexahydroazulen-4-yl (2z)-2-methylbut-2-enoate
(2z)-5-[(1s,4ar,6s,7r,8ar)-7-hydroxy-2,5,5,8a-tetramethyl-6-{[(2z)-2-methylbut-2-enoyl]oxy}-1,4,4a,6,7,8-hexahydronaphthalen-1-yl]-3-methylpent-2-enoic acid
(1s,3r,3as,4s,8ar)-3-hydroxy-3-isopropyl-6,8a-dimethyl-4-{[(2z)-2-methylbut-2-enoyl]oxy}-1,2,3a,4,5,8-hexahydroazulen-1-yl (2z)-2-methylbut-2-enoate
4-[(3e,7e)-10-[(1s,5s)-1-acetyl-5-hydroxy-2,2-dimethylcyclopentyl]-4,8-dimethyldeca-3,7-dien-1-yl]-5-hydroxy-5h-furan-2-one
5-(4-hydroxy-4-methylpent-2-en-1-yl)-8-(hydroxymethyl)-1,5-dimethyl-12-oxabicyclo[9.1.0]dodeca-3,7-dien-2-yl 3-methylbut-2-enoate
(2r,3r,4r,5r)-4-{[(3r,4ar,5s,8as)-3-hydroxy-5-(hydroxymethyl)-2,5,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]methoxy}hexane-1,2,3,5,6-pentol
(2s,3r,4s,5s,6r)-2-{[(1s,4s,4as,7s,8as)-4-hydroxy-7-(2-hydroxypropan-2-yl)-1,4a-dimethyl-octahydronaphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
14-hydroxy-14-(hydroxymethyl)-5,5,9-trimethyl-6-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-7-yl 3-methylbut-2-enoate
(1s,2e,5r,9s,11e,15s,16r)-7,15-dihydroxy-6-[(2s)-1-hydroxypropan-2-yl]-2,9,12,16-tetramethyl-19-oxatricyclo[14.2.1.0⁵,⁹]nonadeca-2,6,11-trien-8-one
(3r)-5-[(1s,2s,4r,4ar,8ar)-1,2,4a,5-tetramethyl-4-{[(2z)-2-methylbut-2-enoyl]oxy}-3-oxo-4,7,8,8a-tetrahydro-2h-naphthalen-1-yl]-3-methylpentanoic acid
(3r,4s,5r,6s,7s,11r,12s,13r,14r)-14-ethyl-4,6,9,12-tetrahydroxy-9-(hydroxymethyl)-3,5,7,11,13-pentamethyl-1-oxacyclotetradecane-2,10-dione
5-{7-hydroxy-2,5,5,8a-tetramethyl-6-[(2-methylbut-2-enoyl)oxy]-1,4,4a,6,7,8-hexahydronaphthalen-1-yl}-3-methylpent-2-enoic acid
(2e,4e,6e)-n-[(3s,6s,9s)-2,5-dihydroxy-6-isopropyl-3,7-dimethyl-8-oxo-1,4,7-triazacyclododeca-1,4-dien-9-yl]octa-2,4,6-trienimidic acid
C22H34N4O4 (418.25799240000003)
(1s,2s,3e,5r,7e,11r)-5-[(3r)-3-hydroxy-4-methylpent-4-en-1-yl]-8-(hydroxymethyl)-1,5-dimethyl-12-oxabicyclo[9.1.0]dodeca-3,7-dien-2-yl 3-methylbut-2-enoate
4-[(7e)-10-[(1s,5s)-1-acetyl-5-hydroxy-2,2-dimethylcyclopentyl]-4,8-dimethyldeca-3,7-dien-1-yl]-5-hydroxy-5h-furan-2-one
(2r,3r,4s,5s,6r)-2-{[(3s,6e,10s)-10,11-dihydroxy-3,7,11-trimethyldodeca-1,6-dien-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(1r,4s,5as,5br,7as,11as,11br,13r,13as)-1,4,13-trihydroxy-5b,8,8,11a,13a-pentamethyl-1h,4h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-chryseno[1,2-c]furan-3-one
(1r,4as,5r,6r,8ar)-6-hydroxy-1,4a,6-trimethyl-5-[(3e)-3-methyl-5-[(2r)-3-methyl-5-oxo-2h-furan-2-yl]pent-3-en-1-yl]-hexahydro-2h-naphthalene-1-carboxylic acid
(2r,3s,4s,5s,6s)-2-{[(1r,2s,4ar,5r,8s,8ar)-5,8-dihydroxy-2-isopropyl-4a,8-dimethyl-octahydronaphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(1r,3as,3br,5as,7r,8s,9as,9bs,11as)-8-(acetyloxy)-1-ethyl-9a,11a-dimethyl-2-oxo-tetradecahydrocyclopenta[a]phenanthren-7-yl acetate
10-hydroxy-5,9,14-trimethyl-6-[(3-methylbutanoyl)oxy]tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-14-ene-5-carboxylic acid
3-[5-(2-{1a,5,6-trimethyl-octahydrocyclopropa[e]naphthalen-5-yl}ethyl)-2-hydroxy-3,6-dihydropyran-2-yl]-4-oxobutanoic acid
(1r,4ar,5r,6r,8ar)-6-hydroxy-1,4a,6-trimethyl-5-[(3e)-3-methyl-5-[(2r)-3-methyl-5-oxo-2h-furan-2-yl]pent-3-en-1-yl]-hexahydro-2h-naphthalene-1-carboxylic acid
4a,5-dimethyl-2-[(2-methylbutanoyl)oxy]-7-oxo-3-(prop-1-en-2-yl)-octahydronaphthalen-1-yl 2-methylbut-2-enoate
(1r,4r,5as,5br,7as,11as,11br,13r,13as)-1,4,13-trihydroxy-5b,8,8,11a,13a-pentamethyl-1h,4h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-chryseno[1,2-c]furan-3-one
(3s,4ar,6ar,8s,10r,10ar,10bs)-3-ethenyl-8-hydroxy-3,4a,7,7,10a-pentamethyl-5-oxo-octahydronaphtho[2,1-b]pyran-10-yl (2z)-2-methylbut-2-enoate
(1s,2s,3e,5r,7e,11r)-5-[(2e)-4-hydroxy-4-methylpent-2-en-1-yl]-8-(hydroxymethyl)-1,5-dimethyl-12-oxabicyclo[9.1.0]dodeca-3,7-dien-2-yl 3-methylbut-2-enoate
(5s)-4-[(1r,3r,4ar,4bs,6as,10as,10bs,12as)-1-hydroxy-4b,7,7,10a-tetramethyl-tetradecahydrophenanthro[2,1-c]pyran-3-yl]-5-hydroxy-5h-furan-2-one
(3r,4as,5r,8s)-4a,5-dimethyl-2-oxo-3-(3-oxoprop-1-en-2-yl)-hexahydro-1ah-naphtho[4,4a-b]oxiren-8-yl decanoate
5-[5-(hydroxymethyl)-5,8a-dimethyl-6-[(2-methylbut-2-enoyl)oxy]-2-methylidene-hexahydro-1h-naphthalen-1-yl]-3-methylpent-2-enoic acid
1-hydroxy-1-isopropyl-3a,6-dimethyl-8-[(2-methylbut-2-enoyl)oxy]-2,3,4,7,8,8a-hexahydroazulen-4-yl 2-methylbut-2-enoate
1-methyl 4-[(1s,4r,9r,10s,13s,14r,16s)-5,5,9-trimethyl-15-oxapentacyclo[11.3.1.0¹,¹⁰.0⁴,⁹.0¹⁴,¹⁶]heptadecan-13-yl]methyl butanedioate
(5s)-5-[(1e)-2-[(3s,4ar,6s,6as,10as,10br)-6-hydroxy-3,4a,7,7,10a-pentamethyl-octahydro-1h-naphtho[2,1-b]pyran-3-yl]ethenyl]-5-hydroxy-4-methylfuran-2-one
5-[(2z,5e)-7-hydroxy-3-(hydroxymethyl)-7-methyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,5-dien-1-yl]-4-(hydroxymethyl)-5h-furan-2-one
2-[(3,10-dihydroxy-2,6,10-trimethyldodeca-6,11-dien-2-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
(2e)-5-[(1r,4as,5s,6r,8as)-5-(hydroxymethyl)-5,8a-dimethyl-6-{[(2z)-2-methylbut-2-enoyl]oxy}-2-methylidene-hexahydro-1h-naphthalen-1-yl]-3-methylpent-2-enoic acid
4-methoxy-2-methyl-3,6-dioxo-5-(pentadec-10-en-1-yl)cyclohexa-1,4-dien-1-yl acetate
2-[(2,10-dihydroxy-2,6,10-trimethyldodeca-6,11-dien-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
4-{1,5-dihydroxy-4-[4-methyl-6-(2,6,6-trimethylcyclohex-1-en-1-yl)hex-3-en-1-yl]pent-3-en-1-yl}-5-hydroxy-5h-furan-2-one
(2s)-2-[(1s,2s,3e,7e,10s)-2-hydroxy-4,8-dimethyl-10-{[(2z)-2-methylbut-2-enoyl]oxy}cyclodeca-3,7-dien-1-yl]propyl (2z)-2-methylbut-2-enoate
(2r,3r,4s,5s,6r)-2-{[(1r,2s,4as,5s,8s,8ar)-5,8-dihydroxy-2-isopropyl-4a,8-dimethyl-octahydronaphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2s,3r,4s,5s,6r)-2-({2-[(2r,4ar,5s,8r,8ar)-5,8-dihydroxy-4a,8-dimethyl-octahydronaphthalen-2-yl]propan-2-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol
2-{[4-hydroxy-6-(2-hydroxypropan-2-yl)-4,8a-dimethyl-octahydronaphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
7-ethenyl-10-hydroxy-1,4a,8-trimethyl-2-[(3-methylbutanoyl)oxy]-2,3,4,4b,5,6,8a,9,10,10a-decahydrophenanthrene-1-carboxylic acid
5-(5-formyl-1,2-dimethyl-4a-{[(3-methylbut-2-enoyl)oxy]methyl}-2,3,4,7,8,8a-hexahydronaphthalen-1-yl)-3-methylpentanoic acid
(1ar,3r,4as,5r,8s,8as)-4a,5-dimethyl-2-oxo-3-(3-oxoprop-1-en-2-yl)-hexahydro-1ah-naphtho[4,4a-b]oxiren-8-yl decanoate
5-[(2z)-4-hydroxy-3-[(3e)-6-(3-hydroxy-2,6,6-trimethylcyclohex-1-en-1-yl)-4-methylhex-3-en-1-yl]but-2-en-1-yl]-4-(hydroxymethyl)-5h-furan-2-one
(2s,3r,4s,5s,6r)-2-{[(3r,6e,10s)-3,10-dihydroxy-2,6,10-trimethyldodeca-6,11-dien-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
5-hydroxy-4-{1-hydroxy-4b,7,7,10a-tetramethyl-tetradecahydrophenanthro[2,1-c]pyran-3-yl}-5h-furan-2-one
3-ethenyl-8-hydroxy-3,4a,7,7,10a-pentamethyl-5-oxo-octahydronaphtho[2,1-b]pyran-10-yl 2-methylbut-2-enoate
(2e,4e)-n-(2,5-dihydroxy-6-isopropyl-3,7-dimethyl-8-oxo-1,4,7-triazacyclododeca-1,4-dien-9-yl)octa-2,4,6-trienimidic acid
C22H34N4O4 (418.25799240000003)
(1s,4s,5s,6r,9r,10r,13r)-10-hydroxy-5,9,14-trimethyl-6-[(3-methylbutanoyl)oxy]tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-14-ene-5-carboxylic acid
(2r,3r,4s,5s,6r)-2-{[(1s,4s,4as,6s,8as)-4-hydroxy-6-(2-hydroxypropan-2-yl)-4,8a-dimethyl-octahydronaphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(3s)-3-[(2s)-5-{2-[(1as,4ar,5s,6s,8as)-1a,5,6-trimethyl-octahydrocyclopropa[e]naphthalen-5-yl]ethyl}-2-hydroxy-3,6-dihydropyran-2-yl]-4-oxobutanoic acid
1-methyl 4-{5,9,13-trimethyl-15-oxapentacyclo[11.3.1.0¹,¹⁰.0⁴,⁹.0¹⁴,¹⁶]heptadecan-5-yl}methyl butanedioate
(3s,4ar,6ar,8s,10r,10ar,10bs)-3-ethenyl-10-hydroxy-3,4a,7,7,10a-pentamethyl-5-oxo-octahydronaphtho[2,1-b]pyran-8-yl (2z)-2-methylbut-2-enoate
2-[(10,11-dihydroxy-3,7,11-trimethyldodeca-1,6-dien-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
(5s)-4-[(3e,7e)-10-[(1s,5r)-1-acetyl-5-hydroxy-2,2-dimethylcyclopentyl]-4,8-dimethyldeca-3,7-dien-1-yl]-5-hydroxy-5h-furan-2-one
(3s,4r,5s)-3-[13-(2h-1,3-benzodioxol-5-yl)tridecyl]-4-hydroxy-5-methyloxolan-2-one
(2e)-5-[(1r,4as,5s,6r,8ar)-5-(hydroxymethyl)-5,8a-dimethyl-6-{[(2z)-2-methylbut-2-enoyl]oxy}-2-methylidene-hexahydro-1h-naphthalen-1-yl]-3-methylpent-2-enoic acid
(2s,3r,4s,5s,6r)-2-{[(6e)-2,10-dihydroxy-2,6,10-trimethyldodeca-6,11-dien-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
4-[(3r,4ar,4bs,10as,10bs,12as)-1-hydroxy-4b,7,7,10a-tetramethyl-tetradecahydrophenanthro[2,1-c]pyran-3-yl]-5-hydroxy-5h-furan-2-one
10-hydroxy-5,9-dimethyl-15-[(3-methylbutanoyl)oxy]-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylic acid
4-methoxy-5-methyl-3,6-dioxo-2-(pentadec-10-en-1-yl)cyclohexa-1,4-dien-1-yl acetate
1-methyl 4-[(1s,4s,5r,9r,10s,13s,14r,16s)-5,9,13-trimethyl-15-oxapentacyclo[11.3.1.0¹,¹⁰.0⁴,⁹.0¹⁴,¹⁶]heptadecan-5-yl]methyl butanedioate
16-{[3-(4-hydroxyphenyl)prop-2-enoyl]oxy}hexadecanoic acid
(3r)-5-[(1s,2r,4as,8ar)-5-formyl-1,2-dimethyl-4a-{[(3-methylbut-2-enoyl)oxy]methyl}-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]-3-methylpentanoic acid
(1s,2r,4ar,4bs,8ar,10r,10ar)-7-ethenyl-10-hydroxy-1,4a,8-trimethyl-2-[(3-methylbutanoyl)oxy]-2,3,4,4b,5,6,8a,9,10,10a-decahydrophenanthrene-1-carboxylic acid
(2s,3r,4s,5s,6s)-2-{[(3r,6e,10s)-2,10-dihydroxy-2,6,10-trimethyldodeca-6,11-dien-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(1s,2r,3r,4ar,5s,8as)-4a,5-dimethyl-2-{[(2r)-2-methylbutanoyl]oxy}-7-oxo-3-(prop-1-en-2-yl)-octahydronaphthalen-1-yl (2e)-2-methylbut-2-enoate
(2r,3r,4s,5s,6r)-2-{[(1r,3ar,4r,5r,7as)-1-hydroxy-1-(hydroxymethyl)-5-isopropyl-7a-methyl-hexahydro-2h-inden-4-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol
3-{2-[(1s,2r,4ar,8ar)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]ethyl}-5-oxo-2h-furan-2-yl tert-butyl carbonate
4-methoxy-5-methyl-3,6-dioxo-2-[(10z)-pentadec-10-en-1-yl]cyclohexa-1,4-dien-1-yl acetate
5-(3-hydroxy-4-methylpent-4-en-1-yl)-8-(hydroxymethyl)-1,5-dimethyl-12-oxabicyclo[9.1.0]dodeca-3,7-dien-2-yl 3-methylbut-2-enoate
(5r)-4-[(1s,3r,4ar,4bs,6as,10as,10bs,12as)-1-hydroxy-4b,7,7,10a-tetramethyl-tetradecahydrophenanthro[2,1-c]pyran-3-yl]-5-hydroxy-5h-furan-2-one
5-hydroxy-5-(2-{6-hydroxy-3,4a,7,7,10a-pentamethyl-octahydro-1h-naphtho[2,1-b]pyran-3-yl}ethenyl)-4-methylfuran-2-one
(1r,2r,3z,5s,7e,11s)-5-[(3s)-3-hydroxy-4-methylpent-4-en-1-yl]-8-(hydroxymethyl)-1,5-dimethyl-12-oxabicyclo[9.1.0]dodeca-3,7-dien-2-yl 3-methylbut-2-enoate
4-[(7e)-10-[(1s,5r)-1-acetyl-5-hydroxy-2,2-dimethylcyclopentyl]-4,8-dimethyldeca-3,7-dien-1-yl]-5-hydroxy-5h-furan-2-one
13-isopropyl-15-[3-methoxy-5-(1h-pyrrol-2-yl)furan-2-yl]-2-azatricyclo[10.2.1.1³,¹⁴]hexadeca-1(15),2,14(16)-triene
(2s,3s,4s,5s,6s)-2-{[(3s,6e,10s)-3,10-dihydroxy-2,6,10-trimethyldodeca-6,11-dien-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(5r)-4-[(3e,7e)-10-[(1s,5s)-1-acetyl-5-hydroxy-2,2-dimethylcyclopentyl]-4,8-dimethyldeca-3,7-dien-1-yl]-5-hydroxy-5h-furan-2-one
(1s,4s,5r,9r,10r,13r,15s)-10-hydroxy-5,9-dimethyl-15-[(3-methylbutanoyl)oxy]-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylic acid
(2s,3r,4s,5s,6r)-2-{[(3r,6e,10s)-2,10-dihydroxy-2,6,10-trimethyldodeca-6,11-dien-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2s,3r,4s,5s,6s)-2-{[(3s,6e,10s)-2,10-dihydroxy-2,6,10-trimethyldodeca-6,11-dien-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
5-(2-hydroxy-2-{6-hydroxy-3,4a,7,7,10a-pentamethyl-octahydro-1h-naphtho[2,1-b]pyran-3-yl}ethylidene)-4-methylfuran-2-one
(2s,3r,4r,5r,6s)-2-{[(1r,3ar,4r,5r,7as)-1-hydroxy-1-(hydroxymethyl)-5-isopropyl-7a-methyl-hexahydro-2h-inden-4-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2e,4e,6e)-n-[(3s,6s,9s)-2,8-dihydroxy-6-isopropyl-3,4-dimethyl-5-oxo-1,4,7-triazacyclododeca-1,7-dien-9-yl]octa-2,4,6-trienimidic acid
C22H34N4O4 (418.25799240000003)
5-[(1e)-2-[(3r,4ar,6s,6as,10as,10br)-6-hydroxy-3,4a,7,7,10a-pentamethyl-octahydro-1h-naphtho[2,1-b]pyran-3-yl]ethenyl]-5-hydroxy-4-methylfuran-2-one
(3s,3ar,4s,5ar,7s,9as,11ar)-3,4,7-trihydroxy-1-[(2s)-1-hydroxypropan-2-yl]-3a,6,6,9a,11a-pentamethyl-3h,4h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-10-one
2-{[4-hydroxy-7-(2-hydroxypropan-2-yl)-1,4a-dimethyl-octahydronaphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
n-(2,5-dihydroxy-6-isopropyl-3,7-dimethyl-8-oxo-1,4,7-triazacyclododeca-1,4-dien-9-yl)octa-2,4,6-trienimidic acid
C22H34N4O4 (418.25799240000003)